PriceTargets.com logo

enGene - ENGN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.22
  • Forecasted Upside: 486.56%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 1 Strong Buy Ratings
$4.30 As of 03/28/2025 05:00 PM ET
▼ -0.45 (-9.47%)

This chart shows the closing price for ENGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
FebMar$4.30Closing price on 03/29/25:
Get New enGene Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ENGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ENGN

Analyst Price Target is $25.22
▲ +486.56% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for enGene in the last 3 months. The average price target is $25.22, with a high forecast of $34.00 and a low forecast of $7.00. The average price target represents a 486.56% upside from the last price of $4.30.

This chart shows the closing price for ENGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
3/246/249/2412/243/254/26$3.01$11$19$26$34Closing price on 03/29/25: $4.30High$34.00Average$25.22Low$7.00




Current Consensus is Buy

The current consensus among 10 contributing investment analysts is to buy stock in enGene.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/7/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/5/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2025

Latest Recommendations

  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/11/2025Morgan StanleyLower TargetOverweight ➝ Overweight$37.00 ➝ $34.00
3/11/2025HC WainwrightReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
2/18/2025Piper SandlerInitiated CoverageOverweight$26.00
2/14/2025UBS GroupDowngradeBuy ➝ Neutral$34.00 ➝ $7.00
12/23/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$18.00 ➝ $18.00
12/23/2024HC WainwrightInitiated CoverageBuy$25.00
12/6/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$18.00 ➝ $18.00
11/27/2024Raymond JamesInitiated CoverageOutperform$23.00
11/18/2024Citizens JmpUpgradeStrong-Buy
11/18/2024JMP SecuritiesInitiated CoverageOutperform$18.00
9/24/2024OppenheimerReiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.00
9/11/2024Morgan StanleyReiterated RatingOverweight ➝ Overweight$40.00 ➝ $40.00
8/28/2024OppenheimerInitiated CoverageOutperform$30.00
4/22/2024Wells Fargo & CompanyInitiated CoverageOverweight$30.00
4/15/2024GuggenheimInitiated CoverageBuy$34.00
3/28/2024UBS GroupInitiated CoverageBuy$37.00
3/8/2024Morgan StanleyInitiated CoverageOverweight$40.00
2/20/2024Leerink PartnrsReiterated RatingOutperform
2/20/2024Leerink PartnersInitiated CoverageOutperform$31.00
(Data available from 3/30/2020 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 71 positive mentions
  • 20 negative mentions
  • 9 very negative mentions
Mentions as of
9/1/2024
  • 13 very positive mentions
  • 77 positive mentions
  • 18 negative mentions
  • 8 very negative mentions
Mentions as of
10/1/2024
  • 11 very positive mentions
  • 78 positive mentions
  • 12 negative mentions
  • 3 very negative mentions
Mentions as of
10/31/2024
  • 4 very positive mentions
  • 21 positive mentions
  • 6 negative mentions
  • 4 very negative mentions
Mentions as of
11/30/2024
  • 9 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2024
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
Mentions as of
1/29/2025
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2025
  • 5 very positive mentions
  • 8 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
Mentions as of
3/30/2025

Current Sentiment

  • 5 very positive mentions
  • 8 positive mentions
  • 5 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

enGene logo
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Read More

Today's Range

Now: $4.30
Low: $4.22
High: $4.83

50 Day Range

MA: $5.96
Low: $4.30
High: $7.39

52 Week Range

Now: $4.30
Low: $4.20
High: $17.54

Volume

33,677 shs

Average Volume

131,097 shs

Market Capitalization

$219.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of enGene?

The following Wall Street analysts have issued research reports on enGene in the last year: Citizens Jmp, Guggenheim, HC Wainwright, JMP Securities, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for ENGN.

What is the current price target for enGene?

0 Wall Street analysts have set twelve-month price targets for enGene in the last year. Their average twelve-month price target is $25.22, suggesting a possible upside of 486.6%. Morgan Stanley has the highest price target set, predicting ENGN will reach $34.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $7.00 for enGene in the next year.
View the latest price targets for ENGN.

What is the current consensus analyst rating for enGene?

enGene currently has 1 hold rating, 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ENGN will outperform the market and that investors should add to their positions of enGene.
View the latest ratings for ENGN.

What other companies compete with enGene?

Other companies that are similar to enGene include Rocket Pharmaceuticals, Xencor, Zymeworks, Xeris Biopharma and Phibro Animal Health. Learn More about companies similar to enGene.

How do I contact enGene's investor relations team?

enGene's physical mailing address is 4001 Kennett Pike Suite 302, Wilmington DE, 19807. The company's listed phone number is 302-273-0765 and its investor relations email address is investors@engene.com. The official website for enGene is www.engene.com. Learn More about contacing enGene investor relations.